Drugs / VER-01
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04930796 | Aug → Nov 2022 | — | Vertanical GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04930809 | Nov 2021 → Jul 2022 | — | Vertanical GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06475001 | Jun 2024 → Jul 2025 | — | Vertanical GmbH | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06956014 | Sep 2026 → Sep 2028 expected | radiculopathy | Vertanical GmbH | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05610813 | Jun 2023 → Oct 2024 | — | Vertanical GmbH | Completed | Met primary |
| Phase 3 | NCT04940741 | Jul 2021 → Mar 2024 | — | Vertanical GmbH | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VER-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04930809 ↗ |
| Route | Oral | “after oral intake” NCT04930796 ↗ |